Defining a clinically significant adverse impact of diagnosing Barrett's esophagus

Journal of Clinical Gastroenterology

Volumn 40, Issue 2, 2006, Pages 109-115

  Rubenstein, Joel H ^a,b   Inadomi, John M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Decision support techniques; Esophageal neoplasms; Quality of life

Indexed keywords

AGE; ARTICLE; BARRETT ESOPHAGUS; CALCULATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DEATH; DECISION SUPPORT SYSTEM; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MONEY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SYMPTOM; THEORETICAL SAMPLE; ADENOCARCINOMA; AGED; COST BENEFIT ANALYSIS; ESOPHAGUS TUMOR; HEALTH SURVEY; MALE; MASS SCREENING; MIDDLE AGED; PRECANCER; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 33645815950     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000196186.19426.4a     Document Type: Article

References (67)

1. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287:1972-1981.
2. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287-1289.
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
4. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and non-surveyed patients. J Thorac Cardiovasc Surg. 1994;108:813-821.
5. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus: does it help? J Thorac Cardiovasc Surg. 1993;105:383-387.
6. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
7. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-1895.
8. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology. 1984;87:927-933.
9. Rodger AJ, Jolley D, Thompson SC, et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30:1299-1301.
10. Cordoba J, Reyes J, Esteban JI, et al. Labeling may be an important cause of reduced quality of life in chronic hepatitis C. Am J Gastroenterol. 2003;98:226-227.
11. Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol. 2005;100:577-580.
12. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at the surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043-2053.
13. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2002;16:41-50.
14. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176-186.
15. Ethiopia A, Gregor JC, Preiksaitis HG, et al. An evaluation of utility measurement in gastroesophageal reflux disease (GERD). Gastroenterology. 1998;114:A116.
16. Fisher D, Jeffreys A, Bosworth H, et al. Quality of life in patients with Barrett's esophagus undergoing surveillance. Am J Gastroenterol. 2002;97:2193-2200.
17. Gerson LB, Ullah N, Chandel A, et al. Patient-derived health state utilities for GERD and Barrett's esophagus: Impact of medical therapy and comorbid conditions. Gastroenterology. 2003;124:S1508.
18. Caygill CP, Reed PI, Johnston BJ, et al. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol. 1999;11:1355-1358.
19. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-215.
20. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
21. Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol. 2000;95:1881-1887.
22. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis, 2nd ed. New York: Oxford University Press, 2000.
23. Green BT, Shaheen NJ, Noble M, et al. Information sources and cancer risk in subjects with Barrett's esophagus. American College of Gastroenterology 68th Annual Scientific Meeting, 2003:118.
24. Gerson LB, Ullah N, Hastie T, et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:524-533.
25. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry. 1999;56:897-904.
26. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633-640.
27. van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut. 1998;43:216-222.
28. Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public [see comment]. Qual Life Res. 2003;12:599-607.
29. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology. 1999;116:277-285.
30. Bonelli L. Barrett's esophagus: results of a multicentric survey. G.O.S.P.E. (Gruppo Operativo per lo Studio delle Precancerosi Esofagee. Endoscopy. 1993;25:652-654.
31. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-124.
32. Weston AP, Krmpotich P, Makdisi WF, et al. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol. 1996;91:981-986.
33. Caygill CP, Reed PI, Hill MJ, et al. An initial comparison of nine centres registering patients with the UK National Barrett's Oesophagus Registry (UKBOR). Eur J Cancer Prev. 1999;8:539-542.
34. Johnston MH, Hammond AS, Laskin W, et al. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol. 1996;91:1507-1511.
35. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249-1256.
36. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol. 1999;94:2037-2042.
37. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-2016.
38. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607-1619.
39. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol. 2000;95:2086-2093.
40. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 1999;94:3413-3419.
41. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985;313:857-859.
42. Williamson WA, Ellis FH Jr, Gibb SP, et al. Barrett's esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212-2216.
43. Sharma P, Reker D, Falk G, et al. Progression of Barrett's esophagus to high grade dysplasia and cancer: preliminary results of the BEST (Barrett's Esophagus Study) trial [Abstract]. Gastroenterology. 2001;120:16.
44. Dent J, Bremner CG, Collen MJ, et al. Barrett's oesophagus. J Gastroenterol Hepatol. 1991;6:1-22.
45. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol. 1998;93:536-541.
46. Schoenfeld P, Johnston M, Piorkowski M, et al. Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's esophagus. Am J Gastroenterol. 1998;93:906-910.
47. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95:1888-1893.
48. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg. 1988;75:760-763.
49. Van der Veen AH, Dees J, Blankensteijn JD, et al. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut. 1989;30:14-18.
50. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331-2338.
51. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol. 1999;94:3420-3426.
52. Menke-Pluymers MB, Schoute NW, Mulder AH, et al. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut. 1992;33:1454-1458.
53. Ellis FH, Jr., Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg. 1997;113:836-846; discussion 846-848.
54. Skinner DB. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg. 1983;85:59-71.
55. Ellis FH Jr, Gibb SP, Watkins E Jr. Esophagogastrectomy: a safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia. Ann Surg. 1983;198:531-540.
56. Nguyen NT, Schauer P, Luketich JD. Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. Surgery. 2000;127:284-290.
57. Wolfe WG, Vaughn AL, Seigler HF, et al. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg. 1993;105:749-755; discussion 755-756.
58. Galandiuk S, Hermann RE, Cosgrove DM, et al. Cancer of the esophagus: the Cleveland Clinic experience. Ann Surg. 1986;203:101-108.
59. DeMeester TR, Zaninotto G, Johansson KE. Selective therapeutic approach to cancer of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1988;95:42-54.
60. Wu YK, Huang KC. Chinese experience in the surgical treatment of carcinoma of the esophagus. Ann Surg. 1979;190:361-365.
61. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381-390.
62. Pera M, Trastek VF, Carpenter HA, et al. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg. 1992;54:199-204.
63. National Center for Health Statistics. Vital Statistics of the United States 2000. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Data Services, 2001.
64. Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications: results of the 1974 American Society for Gastrointestinal Endoscopy survey. JAMA. 1976;235:928-930.
65. Habr-Gama A, Waye JD. Complications and hazards of gastrointestinal endoscopy. World J Surg. 1989;13:193-201.
66. Provenzale D, Kemp A, Arora S, et al. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:670-680.
67. Gorelick AB, Inadomi JM, Barnett JL. Unsedated small-caliber esophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. J Clin Gastroenterol. 2001;33:210-214.